These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34468781)

  • 21. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
    Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
    J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model.
    Lim HI; Yamamoto J; Inubushi S; Nishino H; Tashiro Y; Sugisawa N; Han Q; Sun YU; Choi HJ; Nam SJ; Kim MB; Lee JS; Hozumi C; Bouvet M; Singh SR; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2481-2485. PubMed ID: 32366392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells.
    Oba T; Ono M; Matoba H; Uehara T; Hasegawa Y; Ito KI
    Breast Cancer Res Treat; 2021 Feb; 186(1):37-51. PubMed ID: 33452951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET imaging of tumor hypoxia using 18F-labeled pimonidazole.
    Busk M; Jakobsen S; Horsman MR; Mortensen LS; Iversen AB; Overgaard J; Nordsmark M; Ji X; Lee DY; Raleigh JR
    Acta Oncol; 2013 Oct; 52(7):1300-7. PubMed ID: 23962243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial.
    Askoxylakis V; Dinkel J; Eichinger M; Stieltjes B; Sommer G; Strauss LG; Dimitrakopoulou-Strauss A; Kopp-Schneider A; Haberkorn U; Huber PE; Bischof M; Debus J; Thieke C
    Radiat Oncol; 2012 Sep; 7():157. PubMed ID: 22974533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
    Troost EG; Laverman P; Kaanders JH; Philippens M; Lok J; Oyen WJ; van der Kogel AJ; Boerman OC; Bussink J
    Radiother Oncol; 2006 Aug; 80(2):157-64. PubMed ID: 16905213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eribulin shows high concentration and long retention in xenograft tumor tissues.
    Sugawara M; Condon K; Liang E; DesJardins C; Schuck E; Kusano K; Lai WG
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):377-384. PubMed ID: 28664226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
    Kawano S; Asano M; Adachi Y; Matsui J
    Anticancer Res; 2016 Apr; 36(4):1553-61. PubMed ID: 27069131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts.
    Takahashi M; Miki S; Fujimoto K; Fukuoka K; Matsushita Y; Maida Y; Yasukawa M; Hayashi M; Shinkyo R; Kikuchi K; Mukasa A; Nishikawa R; Tamura K; Narita Y; Hamada A; Masutomi K; Ichimura K
    Cancer Sci; 2019 Jul; 110(7):2247-2257. PubMed ID: 31099446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines.
    Tanaka S; Ishii T; Sato F; Toi M; Itou J
    Biochem Biophys Res Commun; 2020 May; 526(1):154-157. PubMed ID: 32201082
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Qian Y; Von Eyben R; Liu Y; Chin FT; Miao Z; Apte S; Carter JN; Binkley MS; Pollom EL; Harris JP; Prionas ND; Kissel M; Simmons A; Diehn M; Shultz DB; Brown JM; Maxim PG; Koong AC; Graves EE; Loo BW
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1183-1192. PubMed ID: 29859786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.
    Sampson VB; Vetter NS; Zhang W; Patil PU; Mason RW; George E; Gorlick R; Kolb EA
    Oncotarget; 2016 Dec; 7(52):86594-86607. PubMed ID: 27863409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.
    Troost EG; Laverman P; Philippens ME; Lok J; van der Kogel AJ; Oyen WJ; Boerman OC; Kaanders JH; Bussink J
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1803-11. PubMed ID: 18421457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stathmin dynamics modulate the activity of eribulin in breast cancer cells.
    Yoshie M; Ishida A; Ohashi H; Nakachi N; Azumi M; Tamura K
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00786. PubMed ID: 34176226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and Bioevaluation of Novel [
    Yang X; Wang F; Zhu H; Yang Z; Chu T
    Mol Pharm; 2019 May; 16(5):2118-2128. PubMed ID: 30964298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. (18)F-fluoromisonidazole PET reveals spatial and temporal heterogeneity of hypoxia in mouse models of human non-small-cell lung cancer.
    Cui YL; Wang X; Li XF
    Future Oncol; 2015; 11(20):2841-9. PubMed ID: 26361064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple modes of action of eribulin mesylate: Emerging data and clinical implications.
    Cortes J; Schöffski P; Littlefield BA
    Cancer Treat Rev; 2018 Nov; 70():190-198. PubMed ID: 30243063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
    Niwa Y; Asano M; Nakagawa T; France D; Semba T; Funahashi Y
    Anticancer Res; 2020 Dec; 40(12):6699-6712. PubMed ID: 33288563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
    Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
    Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling.
    Nakai S; Tamiya H; Imura Y; Nakai T; Yasuda N; Wakamatsu T; Tanaka T; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Yoshikawa H; Naka N
    Mol Cancer Ther; 2020 Mar; 19(3):742-754. PubMed ID: 31796507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.